Loading
Lynkuet is a once-a-day capsule for moderate to severe hot flushes and night sweats. In Europe it is approved both for the menopause and for hot flushes caused by the hormone-blocking tablets taken after breast cancer treatment.
Elinzanetant (Lynkuet; marketing authorisation holder Bayer AG) has been authorised in the EU since 17 November 2025 (CHMP opinion 18 September 2025) for the treatment of moderate to severe vasomotor symptoms. The EPAR overview says it is used for hot flushes and night sweats associated with menopause or caused by adjuvant endocrine therapy for breast cancer, the oestrogen-blocking treatment given after surgery or other cancer treatment to lower the chance of the cancer coming back. It is taken by mouth once a day at bedtime and is under additional monitoring. In the study of 474 women on adjuvant endocrine therapy that the EMA summarises (OASIS-4, NCT05587296), daily moderate to severe hot flushes fell by around 6 on elinzanetant against around 3 on placebo after 4 weeks, and by around 8 against around 4 after 12 weeks; the effect lasted at least 50 weeks, and sleep and quality of life also improved more than on placebo.
Blocks neurokinin B from attaching to two of its receptors in the brain. Neurokinin B and oestrogen together regulate the brain's temperature control centre; when oestrogen falls during menopause or endocrine therapy the balance is lost and hot flushes follow (EPAR overview, EMA).
1.Elinzanetant slips into a pocket on its target.
| Region | Year | Indication |
|---|---|---|
| EU | 2025 | Moderate to severe vasomotor symptoms, including those caused by adjuvant endocrine therapy for breast cancer (EPAR overview) · Authorised 17 Nov 2025; Bayer AG |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Elinzanetant" OR ABSTRACT:"Elinzanetant" OR TITLE:"Lynkuet" OR ABSTRACT:"Lynkuet" OR TITLE:"elinzanetant" OR ABSTRACT:"elinzanetant") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Elinzanetant, not a curated reading list.
Shares the tags universe-gap, ema-register, supportive.
Shares the tags ema-register, supportive.
Shares the tags ema-register, supportive.
Shares the tags ema-register, supportive.
Shares the tags ema-register, supportive.
Shares the tags universe-gap, supportive.
Shares the tags universe-gap, ema-register.
Shares the tags universe-gap, ema-register.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/